Abstract 1733P
Background
On 24th of February 2022 reality in Ukraine changed. Ukraine became a victim of unfair attack of the neighbouring county. It influenced civilian population hugely, including the most vulnerable - children, elderly and patients. Since then, cancer patients became fighters of two fights - malignant disease and external aggressor. After more than a year of this reality Ukrainian oncologists would like to remind international society that the problem is not solved, and Ukrainians desperately need support.
Methods
It is generalized description of situation in the sphere of oncology in Ukraine since 24th of February 2022.
Results
According to Ukraine's Minister of Health, Victor Lyashko, during the first year of the war in Ukraine 1218 hospitals were damaged, 540 - partially destroyed and 173 destroyed completely. Among them - oncological hospitals. More than a million (∼1.2) Ukrainians currently stay on temporary occupied territories of the country and do not have access to qualified medical care. Around 7 million people had to move to safer areas of the country to stay safe and thousands of cancer patients had to move abroad for further treatment. It influenced the oncological landscape significantly. Oncological centers currently have to deal with 70% more patients than before the war. Moreover, the quantity of advanced stage disease has risen dramatically because a lot of people just couldn’t get medical help in time. Therefore, it caused bigger pressure on the medical system, requiring even more resources when they are so limited. At the same time, all clinical trials were put on pause leaving patients with advanced and rare diseases with no options for further treatment. Luckily, international society is extremely friendly to Ukraine providing Ukrainians with shelters and supplies, both material and intellectual. It helped and is helping a lot. But unfortunately, war is not over, and help is still needed.
Conclusions
The aim of the work is to show how things were going during this year of war and how they are actually going now for word to realize that even during the hardest time there is a place for high quality medical care. That only became possible thanks to huge support of international society, but there is still a lot to do to rebuild and improve reality that was destroyed on 24th of February.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1706P - Time to full approval of novel anticancer medicines granted accelerated approval and implications for reform of the accelerated approval pathway
Presenter: Thomas Hwang
Session: Poster session 23
1707P - Cancer drug prices in the US: Efficacy, innovation, clinical trial evidence, and epidemiology
Presenter: Christoph Michaeli
Session: Poster session 23
1708P - The registration pathways in China for globally developed novel anticancer drugs
Presenter: Da-wei Wu
Session: Poster session 23
1709P - Influence of censoring on conclusions of FDA-approved cancer drugs using the modified time to treatment failure
Presenter: Jonathan Ofer
Session: Poster session 23
1710P - Protocol waivers and consequences on treatment safety and efficacy in the Drug Rediscovery Protocol (DRUP)
Presenter: Laurien Zeverijn
Session: Poster session 23
1711P - The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine
Presenter: Hans Gelderblom
Session: Poster session 23
1712P - Implementation of a molecular pre-screening program (MPP) in a network of public cancer centres for phase I clinical trial (Ph1-CT) candidates: The PREICO program
Presenter: Juan José Soto Castillo
Session: Poster session 23
1713P - Non-inferiority oncology clinical trials in major journals: Purposes, methods and results
Presenter: Rafael Barreto
Session: Poster session 23
1714P - Geographical disparities in access to cancer clinical trials in Korea
Presenter: Sokbom Kang
Session: Poster session 23
1715P - Analysis of the adequacy of control arms in oncology randomized clinical trials published between 2017 and 2021: A meta-research study
Presenter: Alessandro Rossi
Session: Poster session 23